Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: Mol Cancer Ther. 2017 Jun 27;16(10):2058–2068. doi: 10.1158/1535-7163.MCT-16-0660

Figure 2.

Figure 2

AZD1775 enhances the anti-proliferative effect of olaparib on leukemia cells. A. Relative numbers of viable cells treated with DMSO (vehicle control), olaparib (2 uM), and/or AZD1775 (200 nM) for 72 hr. Viable cell counts are normalized to cells receiving no treatment (NT). Results are shown as mean ± SEM from three independent experiments. *, P < 0.05. **, P < 0.01. ***, P < 0.001, ****, P < 0.0001. B. Live cell number of NT AML and ALL cell lines or treated with the indicated concentrations of DMSO (vehicle control), olaparib, and/or AZD1775 for 72 hr, removed from drug and cultured in fresh media for another 72 hr. Results are displayed as mean ± SEM from three independent experiments. Displayed P values were calculated by two-way ANOVA.